Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 4 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1CNS 1

Conditions

Oligodendroglioma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Histiocytosis, Langerhans-Cell 1Glioma 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Astrocytoma 1

Interventions

Specimen Handling 3Cisplatin 3Magnetic Resonance Spectroscopy 2Letrozole 2Human Papillomavirus Recombinant Vaccine nonavalent 2Diosmin 2Carboplatin 2trametinib 1toripalimab 1tocilizumab 1sofosbuvir-velpatasvir drug combination 1ruxolitinib 1rozanolixizumab 1pyrotinib 1pirtobrutinib 1olutasidenib 1obinutuzumab 1niraparib 1naldemedine 1idelalisib 1human papillomavirus vaccine, L1 type 16, 18 1fluciclovine F-18 1enfortumab vedotin 1darolutamide 1dabrafenib 1cabozantinib 1apalutamide 1adacel 1acalabrutinib 1Watchful Waiting 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × dabrafenib × 30 days × Clear all
NCT03975829 2026-06-02

Pediatric Long-Term Follow-up and Rollover Study

Novartis

Phase 4 Recruiting
165 enrolled
CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡